Pre-made Brentuximab benchmark antibody ( Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/Ki-1/D1S166E Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Brentuximab biosimilar, Whole mAb ADC, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.
| Products Name (INN Index) | Pre-Made Brentuximab biosimilar, Whole mAb ADC, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody |
|---|---|
| INN Name | Brentuximab |
| Target | TNFRSF8 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Bristol-Myers Squibb,Celgene Corporation,Dana-Farber Cancer Institute,Fondazione Italiana Linfomi,Fox Chase Cancer Center,Immune Tolerance Network,Lymphoma Academic Research Organisation,Massachusett |
| Conditions Approved | Anaplastic large cell lymphoma,Cutaneous T-cell lymphoma,Hodgkin's disease,Mycosis fungoides,T-cell lymphoma |
| Conditions Active | Adult T-cell leukaemia-lymphoma,Diffuse large B cell lymphoma,Germ cell and embryonal neoplasms,Mastocytosis,Mesothelioma,Non-Hodgkin's lymphoma,Peripheral T-cell lymphoma,Sezary syndrome,Diffuse scl |
| Conditions Discontinued | Graft-versus-host disease,Leukaemia,Multiple myeloma,Solid tumours,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF8 |
| Package |
